By August 2025, research from the RAND American Life Panel showed that approximately 11.8% of American adults (nearly 1 in 8 people) had used GLP-1 medications at least once, marking a dramatic increase in adoption
5.Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE TM Obesity and Pre-diabetes
In line with this data, treatment with the NS5B inhibitor Sofosbuvir revealed no RF dependent differences in IC50 values (Fig
Trinity Meds lists its partner pharmacies by name with publicly available contact information - Belmar Pharmacy (800-525-9473), Strive Pharmacy (855-405-5993), Epiq Scripts (833-654-3553), and Casa Pharma Rx (877-937-6868)
Methodology This analysis is based on 95,854 GLP-1-related consumer conversations collected between January 2022 and December 2025, with 340,725 opinions extracted across forums, social media, and health review sites